HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The PNPLA3 I148M variant is associated with transaminase elevations in type 2 diabetes patients treated with basal insulin peglispro.

Abstract
Basal insulin peglispro (BIL) is a novel insulin with hepato-preferential action. In phase 3 trials, BIL showed significantly improved glycemic control but higher levels of transaminases (alanine aminotransferase (ALT) and aspartate aminotransferase (AST)), triglycerides (TGs) and liver fat content (LFC) compared with insulin glargine (GL). As variants in PNPLA3 (I148M) and TM6SF2 (E167K) are associated with nonalcoholic fatty liver disease, we assessed these variants in type 2 diabetes (T2D) patients randomized to receive BIL (n=1822) or GL (n=1270) in three phase 3 trials. Magnetic resonance imaging assessments of LFC were conducted in a subset of patients (n=296). Analyses showed α-corrected significant increases in change from baseline in AST (P=0.0004) and nominal increases in ALT (P=0.019), and LFC (P=0.035) for PNPLA3 (148M/M) genotypes in the BIL arm at 26 weeks but no significant associations in GL. PNPLA3 (148M/M) was also associated with increases in total cholesterol (P=0.014) and low-density lipoprotein cholesterol (P=0.005) but not with hemoglobin A1c or TG. T2D patients with the PNPLA3 (148M/M) genotype treated with BIL may be more susceptible to increased liver fat deposition. The current data provide further insights into the biological role of PNPLA3 in lipid metabolism.
AuthorsS Pillai, S Duvvuru, P Bhatnagar, W Foster, M Farmen, S Shankar, C Harris, E Bastyr 3rd, B Hoogwerf, A Haupt
JournalThe pharmacogenomics journal (Pharmacogenomics J) Vol. 18 Issue 3 Pg. 487-493 (05 22 2018) ISSN: 1473-1150 [Electronic] United States
PMID29160303 (Publication Type: Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
Chemical References
  • Blood Glucose
  • Cholesterol, LDL
  • Hypoglycemic Agents
  • Insulin Lispro
  • Membrane Proteins
  • Triglycerides
  • basal insulin peglispro
  • Polyethylene Glycols
  • Aspartate Aminotransferases
  • Alanine Transaminase
  • Lipase
  • adiponutrin, human
Topics
  • Adult
  • Alanine Transaminase (blood)
  • Aspartate Aminotransferases (blood)
  • Blood Glucose (drug effects)
  • Cholesterol, LDL (blood)
  • Diabetes Mellitus, Type 2 (blood, drug therapy, genetics, pathology)
  • Female
  • Genotype
  • Humans
  • Hypoglycemic Agents (administration & dosage, adverse effects)
  • Insulin Lispro (administration & dosage, adverse effects, analogs & derivatives)
  • Lipase (genetics)
  • Lipid Metabolism (genetics)
  • Liver (diagnostic imaging, metabolism, pathology)
  • Magnetic Resonance Imaging
  • Male
  • Membrane Proteins (genetics)
  • Middle Aged
  • Polyethylene Glycols (administration & dosage, adverse effects)
  • Polymorphism, Single Nucleotide
  • Triglycerides (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: